Bath & Body Works, Inc. cash flow to debt ratio of 22.24% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Bath & Body Works, Inc.'s free cash flow has increased 31.06% from $660.00M last year to $865.00M, signaling increasing performance

Bath & Body Works, Inc.'s debt to equity ratio is -4.16, signaling that the company spent its equity and risk bankruptcy.

Bath & Body Works, Inc.'s debt to equity ratio is -4.16, signaling that the company spent its equity and risk bankruptcy.

Bath & Body Works, Inc. has a net debt to EBITDA ratio of 2.83x, which is below the 3.00x threshold, indicating healthy leverage and financial stability

Bath & Body Works, Inc.'s interest coverage ratio of 4.19 indicates that earnings with good margin can cover interest payments on company debt

Bath & Body Works, Inc.'s profit margin has decreased (8.12%) in the last year from 10.92% to 10.03%, signaling decreasing performance

Bath & Body Works, Inc.'s short-term assets of $2.02B exceed its short-term liabilities of $1.59B

Bath & Body Works, Inc.'s return on assets of 14.65% is higher than the 5.00% threshold, indicating efficient asset utilization

Bath & Body Works, Inc.'s return on equity of -52.38%, is lower than 15.00%, indicating bad performance

Bath & Body Works, Inc.'s operating cash flow exceeds its net income, indicating high-quality earnings backed by actual cash generation

Bath & Body Works, Inc. had positive net income in 5 out of 5 years, indicating stable and consistent earnings

Bath & Body Works, Inc. has positive free cash flow, indicating the company generates cash after capital expenditures

Bath & Body Works, Inc. has a free cash flow yield of 22.21%, which is above the 2.00% threshold, indicating strong cash generation relative to market value

Bath & Body Works, Inc.'s yearly earnings has decreased 18.67% since last year from $798.00M to $649.00M, signaling decreasing performance

Bath & Body Works, Inc.'s yearly revenue has decreased 0.22% since last year from $7.31B to $7.29B, signaling decreasing performance

ROIC 24.40% (Source: FMP key-metrics). At or above the 10% threshold. Score: 2 of 2. The company is generating returns above the upper end of the typical US weighted-average cost of capital range under this definition of invested capital.

Bath & Body Works, Inc.'s 3-year revenue CAGR of -1.20% is negative, indicating declining revenue over the past 3 years

Bath & Body Works, Inc. had revenue growth in only 1 out of 5 years, indicating inconsistent revenue performance

Bath & Body Works, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Bath & Body Works, Inc. is overvalued relative to its fair value price of 7.24 based on Discounted Cash Flow model

Bath & Body Works, Inc. has an earnings yield of 18.63%, which is above the 4.00% threshold, indicating the stock offers reasonable value relative to its earnings

Bath & Body Works, Inc. is undervalued relative to its fair value price of 27.65 based on EBITDA multiple model

Bath & Body Works, Inc. has an EV/EBITDA ratio of 5.59x, which is below the 20.00x threshold, indicating reasonable valuation relative to its operating earnings

Bath & Body Works, Inc. is undervalued relative to its fair value price of 66.26 based on Earnings Fair Value model

Bath & Body Works, Inc. has a PEG-ratio over 1 which is considered overvalued

Bath & Body Works, Inc. has negative shareholder equity; price-to-book is not meaningful and the check fails

Bath & Body Works, Inc. has a price-to-sales ratio of 0.54x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue